Literature DB >> 31324940

Effect of "ribosome engineering" on the transcription level and production of S. albus indigenous secondary metabolites.

Maria Lopatniuk1, Maksym Myronovskyi1, Alessia Nottebrock1, Tobias Busche2, Jörn Kalinowski2, Bohdan Ostash3, Viktor Fedorenko3, Andriy Luzhetskyy4,5.   

Abstract

Significant resources are invested into efforts to improve the production yields of natural products from Actinobacteria, a well-recognized source of leads for several industries, most notably pharmaceutical one. Introduction of changes into genes for ribosomal protein S12 (rpsL) and/or 16S rRNA methylation (rsmG) is one of traditional approaches (referred to as ribosomal engineering) towards actinobacterial strain improvement. Yet, true potential of ribosome engineering remains unknown as it is currently coupled to empirical selection for aminoglycoside-resistance; rpsL mutations without such phenotypic expression could not be isolated. Here, we report a systematic and rational ribosome engineering approach to study the effect of a range of rpsL mutations on the production level of different biosynthetic gene clusters (BGC). The severe effect of diverse rpsL mutations together with deletion of rsmG engineered in Streptomyces albus has been revealed on the transcription level of several indigenous BGCs. The aforementioned mutations strongly impacted the transcription of indigenous BGCs, possibly because they alter the transcription of BGC-situated and global regulatory genes. The rsmG deletion with certain rpsL mutations can have a synergistic effect on the transcription level of indigenous BGCs. Our work thus provides the first streptomycete platform for rational engineering and study of virtually any nonlethal rpsL mutation. The tremendous effect of ribosome engineering on the transcription profile of the strains was reported for the first time. A library of described S. albus rpsL*/ΔrsmG strains represents a useful tool for overproducing known secondary metabolites and activating silent biosynthetic gene clusters in Actinobacteria.

Entities:  

Keywords:  Natural products; Rational ribosome engineering; Streptomyces; Transcription profile

Year:  2019        PMID: 31324940     DOI: 10.1007/s00253-019-10005-y

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  6 in total

Review 1.  Engineering the Translational Machinery for Biotechnology Applications.

Authors:  Tianwen Wang; Chen Liang; Yafei An; Sa Xiao; Hongjv Xu; Mengyuan Zheng; Lu Liu; Gaozhan Wang; Lei Nie
Journal:  Mol Biotechnol       Date:  2020-04       Impact factor: 2.695

2.  Genetically engineered rpsL merodiploidy impacts secondary metabolism and antibiotic resistance in Streptomyces.

Authors:  Oksana Koshla; Maria Lopatniuk; Oksana Borys; Yuya Misaki; Volodymyr Kravets; Iryna Ostash; Anastasiia Shemediuk; Kozo Ochi; Andriy Luzhetskyy; Victor Fedorenko; Bohdan Ostash
Journal:  World J Microbiol Biotechnol       Date:  2021-03-17       Impact factor: 3.312

3.  Gram-Level Production of Balanol through Regulatory Pathway and Medium Optimization in Herb Fungus Tolypocladium ophioglossoides.

Authors:  Rui-Qi Li; Xiang Liu; Min Zhang; Wei-Qun Xu; Yong-Quan Li; Xin-Ai Chen
Journal:  J Fungi (Basel)       Date:  2022-05-16

4.  Properties of Spontaneous rpsL Mutant of Streptomyces albus KO-1297.

Authors:  A L Shemediuk; B S Dolia; K Ochi; V O Fedorenko; B O Ostash
Journal:  Cytol Genet       Date:  2022-02-11       Impact factor: 0.579

5.  Novel Fredericamycin Variant Overproduced by a Streptomycin-resistant Streptomyces albus subsp. chlorinus Strain.

Authors:  Marta Rodríguez Estévez; Maksym Myronovskyi; Birgit Rosenkränzer; Thomas Paululat; Lutz Petzke; Jeanette Ristau; Andriy Luzhetskyy
Journal:  Mar Drugs       Date:  2020-05-28       Impact factor: 5.118

Review 6.  Microbial production of small peptide: pathway engineering and synthetic biology.

Authors:  Zhiyong Wu; Youran Li; Liang Zhang; Zhongyang Ding; Guiyang Shi
Journal:  Microb Biotechnol       Date:  2021-01-18       Impact factor: 5.813

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.